This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lenfant, C. Search for Related Content PubMed PubMed Citation Articles by Lenfant, C. Related Collections Cardiovascular imaging agents/Techniques Animal models of human disease AHA Statements and Guidelines CT and MRI Pediatric and congenital heart disease, including cardiovascular surgery Cardiac development

(Circulation. 2002;106:1037.)
© 2002 American Heart Association, Inc.

Special Reports

Report of the Task Force on Research in Pediatric Cardiovascular Disease

Claude Lenfant, MD

From the Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, Md.

Correspondence to Claude Lenfant, MD, Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD 20892. E-mail lenfantc@nhlbi.nih.gov

Key Words: cardiovascular diseases • heart diseases • pediatrics

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Since the 1940s, when major breakthroughs occurred in the surgical treatment of congenital malformations, great strides have been made in the treatment of cardiovascular disease in infants and children. Nonetheless, significant difficulties remain that hinder our ability to treat the very youngest and smallest patients with cardiovascular disease, including those still in utero. Heart disease in infants, children, and adolescents is still a large problem, with substantial burden and cost for both families and society.

Although surgical and technological innovations have greatly advanced treatment of cardiovascular disease in adult patients, treatment of infants, children, and adolescents has not kept pace. The most obvious reason for this situation is that children are not simply smaller adults. If they were, the appropriate miniaturization of instruments and equipment, scaling down from adults to children, would be sufficient. However, when considering interventions for neonates, or even fetuses, one must remember that they exhibit marked physiological characteristics that distinguish them from adults, such as increased heart rate and immature tissue development.

To stimulate clinical research and thereby enhance our ability to treat infants, children, and adolescents, the National Heart, Lung, and Blood Institute (NHLBI) has launched 2 major initiatives. First, in May of 2000, we issued a solicitation for the establishment of a Pediatric Heart Disease Clinical Research Network of interactive pediatric clinical research centers (http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-00-013.html). Its purpose is to promote efficient evaluation of innovative treatment methods and management strategies for children with structural congenital heart disease, inflammatory heart disease, heart muscle disease, and arrhythmias. . . . [Full Text of this Article]

This article has been cited by other articles:

				J. Rychik, Z. Tian, M. S. Cohen, S. G. Ewing, D. Cohen, L. J. Howell, R. D. Wilson, M. P. Johnson, H. L. Hedrick, A. W. Flake, et al. Acute Cardiovascular Effects of Fetal Surgery in the Human Circulation, September 21, 2004; 110(12): 1549 - 1556. [Abstract] [Full Text] [PDF]

				R. Chatrath, K. L. Ronningen, P. LaBreche, S. R. Severson, M. Jayachandran, M. P. Bracamonte, and V. M. Miller Effect of puberty on coronary arteries from female pigs J Appl Physiol, October 1, 2003; 95(4): 1672 - 1680. [Abstract] [Full Text] [PDF]